Researchers developed the seats to measure biometrics during ‘natural’ processes
With 1 million new cases of congestive heart failure diagnosed each year, a revolutionary product is making it easier for hospitals to monitor patients with the condition in the comfort of their own homes.
A toilet-seat based cardiovascular monitoring system created by a team of Rochester Institute of Technology researchers, aims to lower the hospital readmission rates of patients with congestive heart failure. The toilet seats, which will be brought through the FDA clearance process by the researchers’ company Heart Health Intelligence, would be purchased by hospitals and issued to heart failure patients after discharge. The toilet seats are equipped to measure the electrical and mechanical activity of the heart, and can monitor heart rate, blood pressure, blood oxygenation levels, and the patient’s weight and stroke volume, which is the amount of blood pumped out of the heart at every beat. Algorithms analyze the data, and with further development, will alert advanced practice providers of a deteriorating condition. A report will be passed along to cardiologists who will then determine if intervention is necessary.
Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that developed the toilet seats.
“Typically, within 30 days of hospital discharge, 25 percent of patients with congestive heart failure are readmitted,” said Conn. “After 90 days of hospital discharge, 45 percent of patients are readmitted. And the Centers for Medicare and Medicaid Services is penalizing hospitals for readmitting patients for heart failure.”
Conn, the company’s chief executive officer, further explains that using the national average for readmission rates, the penalty alone for readmitting 150 patients is approximately $500,000 annually. The total cost of providing 150 patients with their own monitored toilet seats from HHI is $200,000. With that investment, he says, hospital systems will save more than double their initial investment within one year.
According to Conn, who earned three degrees from RIT—a bachelor’s degree and a master’s degree in electrical engineering in 2011 and 2013, respectively, and a doctoral degree in microsystems engineering in 2016—the system will pick up deteriorating conditions before the patients even realize they are symptomatic. And with the rapid data analysis, interventions can be as simple as a drug change or short office visit, instead of an admission to the hospital.
HHI, which joined RIT’s Venture Creations business incubator earlier this year, is now focused on moving the product forward. The team is heavily involved in writing grants for additional funding and networking, and human-subject testing and pre-clinical studies are well underway. Conn and his team are working on approving the product with the FDA and rolling it out across the country.
The Latest on: Congestive heart failure
via Google News
The Latest on: Congestive heart failure
- Patients with heart rhythm disorder warned against heavy alcohol consumptionon December 2, 2020 at 8:05 am
Fourteen drinks a week is linked with a higher risk of health problems including stroke and embolism in patients with atrial fibrillation, according to research published in EP Europace, a journal of ...
- Austin ISD: No appeal process after teacher medical accommodation request deniedon December 2, 2020 at 2:28 am
Teachers are sounding off after medical accommodation requests to work from home are being denied for the spring semester in the Austin Independent School District. “My doctor looked me in the face ...
- Epidemiology Forecast on Myocarditis to 2030 - Current Available Treatments - ResearchAndMarkets.comon December 1, 2020 at 9:00 am
Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of ...
- At high risk of COVID, Trumbull EMS to upgrade heart treatmentson November 29, 2020 at 2:00 am
Getting critical treatment to patients in heart failure has been complicated by COVID-19 since the most effective treatment is by aerosol medication.
- How Organ Care System for Heart Market Will Grow In Coming Future Despite COVID-19 Chaos?on November 24, 2020 at 1:43 am
Research Dive :The outburst of COVID-19 pandemic has left a positive impact on the global organ care system for heart market growth. Growing cases of congestive heart failure (CHF) during Coronavirus ...
- Diabetes drug shows promise in treating and reversing heart failureon November 21, 2020 at 3:00 am
The diabetes drug empagliflozin significantly improved the heart function of people with heart failure. For many, it led to a reversal of the disease.
- Vida Health Launches Virtual Congestive Heart Failure Management Programon November 12, 2020 at 3:17 pm
Vida Health will launch a virtual congestive heart failure management program to its national payer customers in Dec. with a full rollout in Jan. 2021 ...
- Heart Failure Treatmenton November 11, 2020 at 4:00 pm
Harvard Health Publishing: "Heart failure and potassium." Clinical Calcium: "Magnesium in congestive heart failure." ...
- 24-Year-Old With Congestive Heart Failure Encourages Positivity — Joins RTMon November 9, 2020 at 3:33 pm
At just 22 years old, Dantrell Brown was diagnosed with congestive heart failure after losing his breath during a basketball game. Needless to say, the diagnosis rocked his and his fiancée’s ...
- Global Medicines for Congestive Heart Failure Market 2020 Report Explores Key Regions, Company Profile, Opportunity and Challenge to 2025on November 9, 2020 at 9:25 am
Global Medicines for Congestive Heart Failure Market Growth (Status and Outlook) 2020-2025 is a research document which comprises of in-depth data and study of the industry dynamics of this market.
via Bing News